March 1, 2017
Novo Nordisk A/S said on February 28 that it has filed a new drug application in Japan for its once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide for the treatment of type 2 diabetes. Semaglutide stimulates insulin and suppresses glucagon secretion...read more